论文部分内容阅读
探讨人急性髓细胞性白血病 (acutemyeloidleukemia,AML)细胞mdm2及p53基因蛋白表达水平、相互关系及与临床预后的关系。方法 :用免疫组化方法测定mdm2及 p53蛋白表达 ,HPIAS 1000高清晰度病理图像细胞测定系统分析结果。结果 :75%的AML患者表达不同程度的mdm2蛋白 ,且在各种分型中均有mdm2蛋白过度表达者 ;18 75%的AML患者表达p53蛋白;在AML患者中mdm2蛋白阳性同时p53蛋白阴性者占65 63 % ;mdm2表达阳性者其完全缓解率 (29 17% )较mdm2阴性者 (83 3 %)明显减低(P<0 01),mdm2与 p53蛋白均阳性者缓解率最低,而两种蛋白均阴性者均获完全缓解。结论 :在AML患者中有较高水平的mdm2蛋白表达,以mdm2阳性( +)、p53阴性( -)为其主要表达方式 ,且mdm2及p53蛋白表达与临床疗效有密切的关系
To investigate the expression and relationship of mdm2 and p53 gene proteins in human acute myeloid leukemia (AML) cells and their relationship with clinical prognosis. Methods: Immunohistochemistry was used to determine the expression of mdm2 and p53 protein. HPIAS 1000 high-resolution pathological image cytometric analysis system analysis results. Results: 75% of AML patients expressed different levels of mdm2 protein, and mdm2 protein was over-expressed in various types; 18 75% of AML patients expressed p53 protein; mdm2 protein was positive and p53 protein was negative in AML patients. Sixty-three percent of 636.3% of patients with positive mdm2 expression had a complete response rate (29 17%) compared with those with mdm2-negative (83%) (P<0 01), and those with positive mdm 2 and p53 protein had the lowest remission rate. All those who were negative for protein were completely relieved. Conclusion : There is a high level of mdm2 protein expression in patients with AML, mdm2 positive (+), p53 negative (-) as its main expression, and the expression of mdm2 and p53 protein is closely related to the clinical efficacy.